Oesophageal cancer by Lagergren, Jesper et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/S0140-6736(17)31462-9
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Lagergren, J., Smyth, E., Cunningham, D., & Lagergren, P. (2017). Oesophageal cancer. Lancet.
https://doi.org/10.1016/S0140-6736(17)31462-9
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
1 
 
Oesophageal cancer: Seminar 
Authors: Jesper Lagergren (MD, PhD),1,2 Elizabeth Smyth (MB, BCh, MSc),3 David 
Cunningham (FRCP, FmedSc),3 and Pernilla Lagergren (RN, PhD).4 
 
Affiliations: 1 Division of Cancer Studies, King’s College London and Guy's and St Thomas' 
NHS Foundation Trust, London, United Kingdom. 
2 Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska 
Institutet, Karolinska University Hospital, 17176 Stockholm, Sweden. 
3 The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. 
4 Surgical Care Science, Department of Molecular medicine and Surgery, Karolinska 
University Hospital, 17176 Karolinska Institutet, Stockholm, Sweden. 
 
Corresponding author: Professor Jesper Lagergren. Address: Department of Molecular 
medicine and Surgery, Karolinska Institutet. NS 67, 2nd Floor, 171 76 Stockholm, Sweden. 
Telephone: +46 (0)8-5177 6012. Fax: +46 (0)8-517 76280. E-mail: jesper.lagergren@ki.se. 
 
Funding: The Swedish Research Council (839-2008-7496), Swedish Cancer Society (CAN 
2015/460), Royal Marsden/Institute for Cancer Research (RM/ICR) National Institute for 
Health Research (NIHR) Biomedical Research Centre (BRC), and the Karolinska Institutet 
Distinguished Professor Award to Jesper Lagergren (D-02418/2010).  
  
2 
 
Summary 
Oesophageal cancer is a clinically challenging disease requiring a multidisciplinary approach. 
The extensive treatment may be associated with serious limitations in health-related quality 
of life and yet still a poor prognosis. Recent decades have witnessed a gradual improvement 
in prognosis in many countries. Endoscopic procedures have increasingly been used in the 
treatment of premalignant and early oesophageal tumours. Neoadjuvant therapy with 
chemotherapy or chemoradiotherapy has supplemented surgery as standard treatment of 
locally advanced oesophageal cancer. Surgery has become more standardised and 
centralised. There are several therapeutic alternatives for palliative treatment. This review 
aims to provide insights into the current clinical management, on-going controversies and 
future needs in oesophageal cancer.    
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Introduction 
Oesophageal cancer is the 9th most common cancer and the 6th most common cause of 
cancer death globally.1 This cancer is associated with extensive treatment requirements, 
serious limitations in health-related quality of life (HRQOL) and poor prognosis. Curative 
treatment typically includes chemotherapy or chemoradiotherapy followed by extensive 
surgery, often resulting in morbidity and persistent reductions in HRQOL.2 However, recent 
developments have helped improve prognosis and survivorship.    
 
 
Clinical presentation, signs and symptoms 
Most patients seek healthcare following a period of progressive dysphagia and involuntary 
weight loss. Older men are overrepresented in both main histological types, i.e. oesophageal 
squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC). The average 
male-to-female ratio is 3-to-1 for OSCC and 6-to-1 for OAC, although this ratio varies greatly 
across geographical regions.3, 4 Many patients with OSCC have a history of heavy tobacco 
and alcohol use, while patients with OAC may be obese and have chronic gastro-
oesophageal reflux disease. 
 
Incidence and prognosis 
Globally, OSCC is the most common histology, particularly in high-incidence areas in Eastern 
Asia and in Eastern and Southern Africa.1, 5, 6 In the highest-risk region (“oesophageal cancer 
belt”) from Northern Iran through the Central Asia to North-Central China, approximately 
90% of cases are OSCCs.1, 5, 6 While the incidence of OSCC has decreased in many regions, 
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Europe, North America and Australia have witnessed a marked increase in the incidence of 
OAC during the last four decades, which appears to be sustained.7 Thus, the incidence of 
OAC has surpassed that of OSCC in many Western countries.  
 
The prognosis varies between geographical areas, but population-based studies have shown 
an improvement in the overall 5-year survival from <5% in the 1960s to currently about 20% 
in some European countries, the United States and China.8-10 Prognostic factors include 
tumour stage, tumour sub-site and histology, patients’ performance status and co-
morbidities, and HRQOL.8, 11  
 
Pathophysiology, risk factors and prevention 
Squamous cell carcinoma 
The pathophysiological pathway of OSCC is typically initiated by carcinogenic compounds in 
direct contact with the oesophageal mucosa. Mechanical injury, e.g. from achalasia, 
radiation therapy or from swallowing hot beverages or lye, increases vulnerability to 
carcinogenic compounds. The main risk factors for OSCC are tobacco smoking (including 
swallowed toxins from cigarette smoke) and alcohol overconsumption, particularly when in 
combination.12 Among dietary factors, fruit and vegetable intake is protective,13 while intake 
of red meat14 and very hot beverages are risk factors.15 Genetic factors are also involved; a 
pooled analysis of three genome-wide association studies found new susceptibility loci for 
OSCC.16 Tobacco smoking cessation is probably the single most effective primary preventive 
measure.17   
 
Adenocarcinoma 
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The main pathophysiological pathway of OAC is likely to be chronic gastro-oesophageal 
reflux disease (reflux), causing metaplasia from the native squamous cell mucosa to a 
specialised columnar epithelium, entitled Barrett’s oesophagus.18 Barrett’s can progress to 
low-grade dysplasia, high-grade dysplasia, and invasive OAC.18 The main risk factors for OAC 
are reflux, obesity, and male sex, while Helicobacter pylori-infection and dietary intake of 
fruit and vegetables, and possibly also non-steroidal anti-inflammatory drugs, are 
protective.19 The increasing prevalence of reflux and obesity, combined with a decreasing 
prevalence of Helicobacter pylori-infection, probably contribute to the increasing incidence 
of OAC.19  Research has now identified risk loci for Barrett’s oesophagus associated 
carcinogenesis.20-23 These findings could be used for research examining tailored prevention 
in individuals at high risk of OAC. There is presently limited scientific evidence supporting 
specific preventive measures in OAC,24 but aspirin and antireflux therapy are being tested an 
RCT of patients with Barrett’s oesophagus (AspECT).  
 
Genetics 
Recent developments in high throughput genomic technologies have led to an improved 
understanding of molecular underpinnings of OSCC and OAC. The global cancer genome 
atlas project (TCGA) characterised 164 oesophageal cancers using multiple platforms, and 
OSCC and OAC demonstrated distinct profiles in copy number alterations, methylation 
patterns, and RNA and microRNA expression (Table 1).25 In particular, OSCC was associated 
with a pattern of C>A substitutions, overrepresented in tobacco smokers, and further 
comprehensive molecular characterisation suggested that OSCC is more similar to squamous 
cell carcinoma of the head-and-neck than to OAC. Similarly, OAC demonstrated copy 
number, RNA and methylation patterns closer to gastric adenocarcinoma than OSCC. The 
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results of this study support treating OSCC and OACC as different disease entities, as the 
genomic, transcriptomic and epigenetic changes identified in each cancer reflect underlying 
divergent aetiologies and tissues of origin.25 
      
Considering the oncogenic drivers, the most commonly mutated genes in OSCC are TP53, 
NFE2L2, MLL2, ZNF750, NOTCH1 and TGFBR2, whereas for OAC these are TP53, CDKN2A, 
ARID1A, SMAD4 and ERBB2. Copy number changes also differ; for OSCC the most commonly 
identified copy number alterations amplifications in SOX2, TERT, FGFR1 and MDM1, with 
common deletions of RB1, whereas in OAC amplification of ERBB2, VEGFA, GATA6, CCNE1 
and deletion of SMAD4 are more common. Combined pathway analysis suggests that OSCC 
and OAC have frequent alterations of cell cycle regulators such as CCND1, CCNE1, CDK6 or 
RB1 via distinct mechanisms. This suggests that cell cycle related tyrosine kinase inhibitors 
could be a therapeutic strategy. However, in contrast to gastric adenocarcinoma, no 
microsatellite unstable or Epstein-Barr driven cancers were found in the oesophageal TCGA 
cohort.25   
 
OAC has also been characterised into three distinct subgroups using whole genome 
sequencing based on 129 samples.26 These subtypes were characterised by defects in 
homologous recombination repair, a T>G mutation pattern with a high mutational load or a 
C>A/T mutation pattern associated with an aging imprint. It is possible that each of these 
subtypes have differential sensitivity to targeted therapy, e.g. poly ADP ribose polymerase 
(PARP) inhibitors for homologous recombination repair subtype and immunotherapy for 
high mutational burden. However these findings require clinical validation.26           
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Diagnostic investigations 
Diagnosis 
The presence of oesophageal cancer is determined by endoscopy (Figure 1) with biopsies for 
histopathological confirmation. Endoscopy also provides information of the tumour sub-
location and local extent, and the presence and extent of Barrett’s. After the diagnosis is 
established, computerised tomography of the neck, chest and abdomen assessing distant 
metastasis will guide whether treatment will follow a curative or palliative route.   
  
Operability 
Treatment recommendations rely on tumour stage and patient fitness. Tumour stage is 
currently based on the 7th edition of the TNM-classification, which introduced a more 
detailed assessment of number of metastatic lymph nodes. In the up-coming 8th edition, 
clinical, pathological and post neoadjuvant pathological staging will be separated, and the 
pT1-category will be separated into pT1a and pT1b.27 Tumours with their epicentre >2cm 
below the oesophago-gastric junction (Siewert type III) are classified as gastric cancers, even 
if they involve the oesophagus. The Siewert classification is widely used to categorise 
tumours near the oesophago-gastric junction. Tumours with their epicentre 1–5 cm above 
this junction are categorised as type I, tumours within 1 cm above and 2 cm below this 
junction as type II, and tumours 2–5 cm below the junction are type III cancers.28 In early 
lesions, endoscopic mucosal resection provides a good specimen for histopathological 
assessment. Staging measures for more advanced tumours include positron-emission 
tomography-computerised tomography (PET-CT) and endoscopic ultrasound,29, 30 
Laparoscopy and bronchoscopy are indicated if there is suspicion of abdominal tumour 
spread and tumour overgrowth on bronchi, respectively.29, 31 Laparoscopy can also uncover 
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tumoural extension on the gastric part for junctional adenocarcinomas, identify co-
morbidities (e.g. cirrhosis) and be used for placement of feeding tube if required.  
 
There is limited evidence of the evaluation of physical fitness when considering treatment 
recommendations. However, biological age, co-morbidity, cardiopulmonary capacity, and 
nutritional status should be considered prior to consideration of extensive surgery, and 
patients should be assessed by an experienced anaesthetist.32 Consultation of cardiologists 
and dietitians, and a treadmill test and spirometry can add valuable information.33, 34 For 
older patients, oncogeriatric assessment may be helpful prior to initiating therapy. 
Interestingly, HRQOL measures can predict fitness and prognosis.11, 35, 36 An on-going RCT is 
assessing the role of prehabilitation (including physical, nutritional psychological care) of 
patients before curative treatment.37 
 
Treatment recommendations 
Multidisciplinary assessment and determination of a treatment plan has been shown to 
improve clinical decision-making in oesophageal cancer and should be mandatory.38-40 
Ideally the multidisciplinary team includes expertise in pathology, radiology, endoscopy, 
medical oncology, radiotherapy, surgery, nursing, dietetics and other relevant specialists as 
needed, e.g. laryngologists, physiotherapists and social workers.41 Treatment plans depend 
on clinical tumour stage, sub-site and histology of the tumour, performance status, and co-
morbidity. Finally, the team meeting provides an opportunity to follow-up treatment results 
and for recruiting patients to research studies. 
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Curative treatment 
Endoscopic treatment 
Endoscopic techniques, mainly radiofrequency ablation, endoscopic mucosal resection and 
endoscopic submucosal dissection, are increasingly used for the prevention and curative 
treatment of early oesophageal lesions.42, 43 Most research has examined Barrett’s 
oesophagus and early OAC, but some studies also support ablation therapies in early 
OSCCs.44, 45 Endoscopic mucosal resection combined with radiofrequency ablation can 
successfully prevent cancer progression in patients with high-grade dysplasia, and are 
increasingly also used in patients with low-grade dysplasia, even if multifocal.46-49 Endoscopic 
removal for the small proportion of patients with early (T1) oesophageal cancer has 
increased during the last few years.42 Superficial oesophageal cancer can be successfully 
removed by means of endoscopic submucosal dissection in 90% (95% confidence interval 
[CI] 87-93%) of cases; the main complication is a 5% (95% CI 3-8%) risk of stenosis, which can 
be managed with endoscopic dilatation.50 Compared to endoscopic mucosal resection, 
endoscopic submucosal dissection offers a higher rate of complete resection of early cancer 
(92.7% versus 52.7%) and a lower rate of local tumour recurrence (0.3% versus 11.5%).51 
These organ-sparing procedures offer great HRQOL benefits compared to oesophagectomy, 
and clinical guidelines recommend endoscopic mucosal resection or endoscopic submucosal 
dissection rather than surgery for T1a OAC in specialised centres.38 However, there remains 
a 5% and 17% risk of lymph node metastasis in intra-mucosal (T1a) cancer and submucosal 
cancer (T1b), respectively.42 Moreover, endoscopic therapy is associated with an increased 
risk of local tumour recurrence compared to surgery.52 Thus, patients with superficial 
submucosal infiltration (T1b) oesophagectomy optimises the prognosis, while in patients 
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unfit for surgery, endoscopic resection is a good alternative. The learning curve associated 
with these therapies indicates the need for centralisation.53 
 
Oncological treatment 
In patients with locally advanced (T3-T4 or cN1-N3) oesophageal cancer, chemotherapy or 
chemoradiotherapy plus surgery is required in addition to surgery; the differential sensitivity 
of OSCC and OAC to radiotherapy leads some centres to vary in treatment approaches across 
these histological subtypes (Figure 2) (Table 2). Meta-analysis of 24 randomised trials 
suggests that both neoadjuvant chemotherapy and chemoradiotherapy improve overall 
survival for patients with operable oesophageal cancer (hazard ration [HR] for chemotherapy 
0.87, 95% CI 0.79-0.96; HR for chemoradiotherapy 0.78, 95% CI 0.70-0.88).54 Neoadjuvant 
oncological treatment for very early tumours not suitable for local ablation is less well 
defined. One randomised clinical trial (RCT) demonstrated no difference for stage I and II 
tumours treated with neoadjuvant cisplatin and 5-fluororuracil chemoradiotherapy (45Gy in 
25 fractions) compared to surgery alone.55 Therefore it is recommended that patients with 
≤T2N0 tumours proceed directly to surgery, although reliably identifying these patients with 
pre-operative investigations can be challenging. For all patients undergoing neoadjuvant 
treatment, restaging is recommended before oesophagectomy.38 Nutritional assessment is 
recommended as malnutrition is common, and if enteral feeding is required, jejunostomy 
placement is preferable to stenting for resectable cancer.38, 56  
 
Squamous cell carcinoma 
In an RCT (OE02), 247 (of 802) patients with OSCC were randomised to surgery alone or 
neoadjuvant chemotherapy with 2 cycles of  chemotherapy with cisplatin (80mg/m2 x 96 
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hours) and fluorouracil (1000 mg/m2 x 96 hours) followed by surgery.57 Long-term follow-up 
demonstrated an overall survival benefit for OSCC patients treated with chemotherapy (HR 
0.86, 95% CI 0.71-1.05).58 A more contemporary RCT (CROSS) evaluated a regimen of weekly 
chemotherapy (carboplatin with an area under the curve of 2mg/ml/min and paclitaxel 
50mg/m2) for 5 weeks in conjunction with concurrent radiotherapy (41.4Gy in 23 fractions 
five days/week).59 Among 84 patients with OSCC (of 368), those treated with surgery alone 
had a median survival of 21.1 months compared to 81.6 months in the chemoradiotherapy 
group (HR=0.48, 95% CI 0.28-0.83).60 These results have led to the adoption of the CROSS 
regimen as a standard of care for many OSCC patients undergoing oesophagectomy. 
However, OSCC may not always require surgery as several RCTs have demonstrated similar 
survival when comparing definitive chemoradiotherapy with neoadjuvant 
chemoradiotherapy and surgery, especially in patients with a response to 
chemoradiotherapy.61, 62 However, there are no trial results which directly compare the 
watch and wait versus immediate surgery approaches, but research in this area is on-going. 
Because local recurrence rates are higher with a non-surgical approach, close surveillance 
and salvage surgery, when indicated, are recommended as this may provide survival 
comparable to planned chemoradiation and oesophagectomy.63  
 
Adenocarcinoma 
Neoadjuvant chemotherapy: OACs are less radiosensitive than OSCCs and all operable OAC 
patients with potentially curable cancer should be considered for neoadjuvant 
chemotherapy or chemoradiotherapy followed by surgery. Standard chemotherapy is 
cisplatin-fluoropyrimidine-based, which improved the survival in three RCTs (OE02, MAGIC 
and FNCLCC/FFCD).57, 58, 64, 65 In OE02, 802 oesophageal cancer patients (n=533 OAC) were 
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randomised to 2 cycles of chemotherapy with cisplatin and fluorouracil plus surgery or 
surgery alone, showing a 5% increase in 5-year survival for OAC patients treated with 
chemotherapy.58 Another RCT (OE05) compared 2 cycles of neoadjuvant cisplatin and 
fluorouracil with 4 cycles of epirubicin, cisplatin and capecitabine (ECX) for resectable OAC, 
and although more intensive chemotherapy was associated with an improved pathological 
tumour response, the survival was similar.66 Therefore, whenever neoadjuvant 
chemotherapy alone is preferred, doublet chemotherapy is recommended.        
 
Perioperative chemotherapy: Perioperative chemotherapy is an alternative approach for 
OAC. Two RCTs (FNCLCC/FFCD, including 75% [n=58/503] OAC; and MAGIC, including 26% 
[n=164/224] OAC) randomised patients to perioperative cisplatin plus fluorouracil or 
epirubicin plus cisplatin and fluorouracil (ECF) regimens, respectively, and both trials 
reported a 13-14% improved 5-year survival.64, 65 Post-operative chemotherapy was a 
component in these trials, and patients with adequate performance status following surgery 
should therefore also be treated in the adjuvant setting. Perioperative chemotherapy may 
give the opportunity to treat patients who have derived the most benefit from 
chemotherapy in the neoadjuvant setting with further treatment following surgery. 
Metabolic imaging using a reduction in 18-F-fluoro-deoxy-glucose uptake in the primary 
tumour with PET following one cycle of chemotherapy is predictive of overall survival in 
patients with resectable oesophageal or junctional adenocarcinoma.67-69 Although 
promising, evaluation of chemotherapy response using metabolic imaging such as PET 
requires validation in larger studies and is not recommended as standard practice.  
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Neoadjuvant chemoradiotherapy: Neoadjuvant chemoradiotherapy may also be considered 
for OAC patients.60, 70 The CROSS trial randomised 275 OAC (of 368) patients to 
chemoradiotherapy followed by surgery or to surgery alone.60 Survival was improved in the 
chemoradiotherapy group (HR=0.73, 95% CI 0.55–0.98), although the magnitude of this 
benefit was less than that achieved for OSCC and following adjustment the difference in 
survival for OACC was not statistically significant.60 However, despite this, no significant 
interactions between treatment effect and histological subgroup were identified.60 
Neoadjuvant chemoradiotherapy should be restricted to patients with characteristics similar 
to those in CROSS, i.e. ≤T3 tumours which are <5cm in width and <8cm in length. Alternative 
chemoradiotherapy regimens include cisplatin and oxaliplatin plus fluoropyrimidines.71 
There are no data directly comparing neoadjuvant chemoradiotherapy and neoadjuvant or 
perioperative chemotherapy, but consensus opinion is that both are valuable options, 
however significant (≥grade 3) toxicities such as neutropenia and nausea are less common 
with CROSS type chemoradiotherapy.59, 64, 72 Induction chemotherapy followed by 
chemoradiotherapy has not improved survival in several small trials and therefore remains 
an investigational approach.73, 74 Randomised trials comparing neoadjuvant chemotherapy to 
chemoradiotherapy are currently ongoing (NCT01726452, NCT02509286). 
  
Definitive chemoradiotherapy  
Chemoradiotherapy is superior to radiotherapy for patients with OSCC or OAC who are not 
surgical candidates, including patients with cervical oesophageal tumours. The most 
frequently used definitive chemoradiotherapy regimen is cisplatin (75mg/m2), 5-fluororacil 
(1000mg/m2 infusion daily for 4 days), plus radiotherapy (50Gy). In an RCT, this 
chemoradiotherapy regimen offered a median survival of 12.5 months compared to 8.9 
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months for 64Gy radiotherapy alone.75 Oxaliplatin-based definitive chemoradiotherapy is 
associated with comparable survival to cisplatin-based treatment, but with a different 
toxicity spectrum.71 Therefore, oxaliplatin or cisplatin are both evidence-based treatment 
choices in combination with radiotherapy in this setting. Notably, the radiation dose in 
CROSS (41.4Gy) is less than the standard radiation dose which is used in definitive 
chemoradiotherapy regimens. Intensification of radiotherapy to higher than standard doses 
did not improve local control or survival in one RCT (INT0123), and there are no RCTs 
supporting the use of brachytherapy in this setting.76 However, intensification of 
radiotherapy dosing remains an area of active research as does development of a “watch 
and wait” strategy following chemoradiotherapy for both OAC and OSCC (NCT02741856,  
ISRCTN01483375, NCT01348217, NTR4834, NCT02551458).  
  
Surgical treatment 
Surgery remains a single modality treatment for early tumour stages, and for cT2N0 and 
T1a/T1b cancers after non-radical or failed endoscopic mucosal resection or endoscopic 
submucosal dissection,55 but is combined with neoadjuvant therapy for locally advanced 
oesophageal cancer.77 Oesophagectomy typically includes the removal of most of the 
oesophagus together with the cardia and lesser curve of the stomach (Figure 3). Some issues 
related to oesophagectomy deserve special attention.  
 
Surgical approach 
Tumour-free resection margins are prognostically important.78, 79 This can be accomplished 
through alternative approaches, including right-sided or left-sided thoraco-abdominal or 
transhiatal approaches using open or minimally invasive techniques.31, 80 Earlier studies 
15 
 
examining minimally invasive surgery showed a high risk of complications, possibly related to 
learning curve issues, while recent data show accelerated recovery, which has prompted its 
increased use.81, 82 On-going RCTs are comparing postoperative outcomes following 
minimally invasive procedures and open surgery, where HRQOL is a key outcome 
(ISRCTN59036820, NCT01544790, NTRTC2452). Transhiatal and minimally invasive surgery 
seem to be associated with fewer pulmonary complications compared to thoraco-abdominal 
approaches.83, 84 There are no major differences in survival between any of the established 
approaches.31, 80, 82, 85, 86 Standardisation of the surgical approach might be a more important 
prognostic factor than selecting one specific procedure over another.87 Alternatively, 
providing the surgeon has sufficient experience of various surgical approaches, the approach 
can be tailored depending on tumour and patient characteristics. However, the learning 
curve for surgeons associated with the adoption of new approaches should be taken into 
account.88   
 
Volume  
Annual hospital and surgeon volume of oesophagectomy influence short- and long-term 
mortality.89 High-volume hospitals had lower overall mortality compared to low-volume 
hospitals (HR=0.82, 95% CI 0.75-0.90). A cohort study found that surgeon volume was a 
stronger prognostic factor than hospital volume after mutual adjustment.90 Even 
experienced surgeons who start to perform oesophagectomies have a learning curve before 
the survival outcome for their patients is stabilised.88 Taken together, available scientific 
evidence supports centralisation of oesophagectomy.  
  
Lymphadenectomy 
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Research findings advocating extensive lymphadenectomy91 have been challenged in recent 
large cohort studies showing no association between the number of resected nodes and 
survival after adjusting for surgeon volume.92, 93 Recent data indicate that knowledge of 
location of lymph node metastasis allows for a tailored lymphadenectomy with good 
sampling for tumour staging and possibly better outcomes.94, 95 Moreover, extensive 
lymphadenectomy does not seem to have any adverse effect on patients' postoperative 
HRQOL.96 Taken together, current evidence indicates that a moderate and tailored 
lymphadenectomy providing a sufficient assessment of the pathological tumour stage is 
adequate.  
 
Survivorship  
Patients who have undergone oesophagectomy face some specific survivorship issues, 
including poor HRQOL, eating difficulties and malnutrition, in addition to a limited chance of 
long-term survival. A recent meta-analysis showed long-lasting deterioration in several 
HRQOL aspects, including social functioning, role functioning and increased symptoms of 
fatigue, pain, cough, dry mouth and reflux.97 Additionally, patients often experience major 
social and emotional changes, and they might have an increased risk of developing 
psychiatric disorders, which in turn decreases survival.98  
 
Some patient and tumour characteristics reduce postoperative HRQOL, including co-
morbidity, advanced tumour stage (III-IV), proximal tumour location and OSCC histology.99 
Neoadjuvant therapy has a negative influence on HRQOL aspects during treatment, except 
for dysphagia which is usually relieved.100, 101 However, most patients recover in their HRQOL 
before surgery,102 and there is no difference in postoperative recovery between patients 
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receiving neoadjuvant therapy and those undergoing surgery alone.103 A recent multi-centre 
study found a detrimental impact of definitive chemoradiotherapy for localised oesophageal 
cancer on most HRQOL aspects, but many of these changes usually resolved within 6 months 
of treatment,104 and HRQOL recovery was faster than after oesophagectomy. Surgical 
technical factors, i.e., surgical approach, extent of lymphadenectomy, blood loss or 
operation time, seem to have little influence on postoperative HRQOL.96, 105, 106 Early 
postoperative complications, however, have profound negative effects both in the short and 
long term.107 A recent population-based cohort study found that several HRQOL measures 
are strongly negatively affected up until 10 years after surgery, e.g. reflux, dysphagia and 
eating difficulties (Figure 4).108  
 
Weight loss and malnutrition, before, during and after treatment, are major concerns in 
most oesophageal cancer patients.109 The surgical resection results in a loss of stomach 
reservoir and is associated with several functional and mechanical issues, and also 
malabsorption,110 which contribute to eating difficulties and weight loss. Approximately two 
thirds of patients lose over 10% of their preoperative weight and one in five patients may 
lose over 20% of their preoperative weight within 6 months of oesophagectomy.111 
Nutritional deficiencies, e.g. in vitamin B and folate, may require vitamin or mineral 
supplementation. It is recommended that patients are counselled by a dietician at the time 
of diagnosis for assessing the need for enteral nutrition during neoadjuvant therapy, e.g. by 
supplying the patient with a jejunostomy. There is also some evidence from RCTs showing 
shortened length of hospital stay and improved clinical outcomes of using jejunostomy in 
the postoperative period,112 including continued use at home.113     
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Palliative treatment  
Most patients diagnosed with oesophageal cancer are not eligible for curative therapy or will 
develop tumour recurrence despite curatively intended treatment.58-60 Advanced tumour 
stage at diagnosis (e.g. T4b and M1) suggests palliative treatment. There is limited evidence 
how to select patients for palliative regimen based on other conditions, but this should be 
based on a balanced evaluation of fitness as described above. Palliative therapy aims to 
control disease-related symptoms, preserve as good HRQOL as possible, and prolong 
survival. The median survival in patients with metastatic oesophageal cancer without 
treatment is only a few months. 
 
Local treatment 
Dysphagia is a predominant problem. Oesophageal stenting with self-expanding metallic 
stents usually offers rapid partial relief of dysphagia, and is superior to thermal and chemical 
ablative therapies, at least regarding side-effects and need for re-interventions.114 Survival is 
not related to whether or not the stent is covered.115 Intraluminal brachytherapy may 
provide a slight survival benefit and better longer term HRQOL compared to stenting.114 The 
optimal treatment for dysphagia might be stenting plus brachytherapy.114 Interestingly, a 
recent RCT of 160 patients indicated a longer median survival if the stent was loaded with 
radioactive seeds (177 versus 147 days, p=0.0046).116 However, if chemotherapy is planned 
it often provides relief of dysphagia obviating the need for local treatment. Dysphagia may 
also be palliated by external radiotherapy.   
 
Systemic treatment 
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Chemotherapy improves survival compared to best supportive care alone,117 but the survival 
benefit is modest and must be weighed against the side-effects of chemotherapy. No 
randomised phase III trials exist relating to the palliative treatment of OSCC, and data are 
usually extrapolated from OAC studies. A thorough discussion with the patient and family 
should provide them with a realistic view of the expected advantages and disadvantages of 
chemotherapy. In patients with metastatic oesophageal cancer, trial-eligible patients with a 
good performance status (0-1) have a median survival with first line chemotherapy of <1 
year.64, 118, 119 First-line chemotherapy usually includes platinum and fluoropyrimidine, and 
the addition of a third drug may be considered for fit patients. A non-inferiority RCT (REAL-2) 
demonstrated equivalence of cisplatin and oxaliplatin, and also comparable outcomes for 
infused 5-fluororuacil and capecitabine.120 Triplet combinations include epirubicin or 
docetaxel as a third drug, which may improve tumour response, but also increase toxicity.64, 
118 In particular, the original docetaxel, cisplatin, and 5-fluoruracil regimen is associated with 
high rates of neutropenia and RCTs have evaluated modifications of this regimen to 
ameliorate this toxicity. Furthermore, the role of anthracylines in providing additional 
benefit has been challenged.121, 122 OAC patients should have their tumour tested for 
overexpression of the HER2 protein, and if high level HER2 expression is demonstrated the 
anti-HER2 monoclonal antibody trastuzumab could be used in conjunction with cisplatin-
fluoropyrimidine chemotherapy. In an RCT (TOGA study), patients with HER2 IHC 3+ or IHC 
2+ FISH positive treated with trastuzumab plus chemotherapy had a median survival of 16.0 
months, compared to 11.8 months for patients treated with chemotherapy alone (HR 0.65, 
95% CI 0.51-0-83).123  
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Second-line chemotherapy may be considered for patients with maintained performance 
status (0-1); the average absolute survival benefit with cytotoxic chemotherapy is 6 weeks 
leading to a median overall survival of approximately 5 months.124-126 Appropriate drugs 
include docetaxel, paclitaxel and irinotecan. The anti-VEGFR2 monoclonal antibody 
ramucirumab provides equivalent benefit to cytotoxic chemotherapy for patients with 
metastatic OAC when used as a single second-line agent.127 In combination with paclitaxel, 
ramucirumab is associated with a small gain in median survival (9.6 months compared to 7.4 
months with paclitaxel alone; HR=0.81, 95% CI 0.68-0.96).124  
 
Emerging therapies 
The aggressive nature of oesophageal cancer with early spread, rapid tumour recurrence 
and poor prognosis highlight the need for research examining novel medical therapies.128 
Recent efforts to molecularly characterise oesophageal cancer have identified subgroups of 
patients who might benefit from targeted therapies in future. However, with the exception 
of HER2 positive tumours, RCTs of targeted therapies, including those targeting the EGFR 
and MET pathways, have thus far not been successful.129, 130 Failure to use biomarker 
selection or inadequate validation of biomarkers may be responsible in part for these 
failures. However, co-amplification of receptor tyrosine kinases, intra-tumour heterogeneity 
of copy number alteration and mutations in oesophageal cancers also leads to attenuation 
of the clinical benefit for targeted therapy.26, 131, 132 Emerging targets of therapeutic interest 
in oesophageal cancer include dysregulation cell cycle regulators such as CDK6 which  have 
been successfully targeted in breast cancer by palbociclib and ribocicib, and impaired DNA 
damage repair mechanisms which have been exploited in ovarian cancer using olaparib and 
rucaparib).133-136 Finally, immunotherapy using checkpoint inhibitors such as programmed 
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cell death protein 1 (anti-PD-1) antibodies has resulted in survival benefits for patients with 
some other cancers, and gastro-oesophageal cancer is an attractive target for immuno-
oncology intervention due to its relatively high mutation burden.137-140 Results from early 
phase trials in oesophageal cancer have been encouraging with response rates to the anti-
PD1 antibody pembrolizumab reported as 29% for OSCC and 40% for OAC in an RCT of 23 
programmed death-ligand 1 positive patients.141 PD-L1 negative gastro-oesophageal cancer 
patients also respond to checkpoint inhibitor therapy; the radiological response rate was 
12% in PD-L1 negative patients treated with the anti-PD-1 antibody nivolumab, and 
radiological response rates were incremented for both PD-L1 positive and negative patients 
when the anti-CTLA4 antibody ipilimumab was added to nivolumab therapy.142 The promise 
of personalised immunotherapy for solid tumours could also be realised for oesophageal 
cancer, as adoptive T cell transfer of mutation specific T-cells have now been associated with 
a sustained radiological response in epithelial tumours such as cholangiocarcinoma.143 
However, as autologous adoptive T-cell transfer requires considerable expertise, alternative 
forms of personalised immunotherapy such as CAR-T cells which have been successful in 
haematological malignancies may be more widely applicable.144 CAR-T cells are in early 
development for gastrointestinal cancers, selection of the most safe and specific target 
antigen will be of key importance; targets currently being investigated relevant to 
oesophageal cancer include HER2, MUC1, CEA and EpCAM 
(www.clinicaltrials.gov/ct2/results?term=CAR-T+gastric&Search=Search). 
 
Best supportive care 
Rapidly progressive dysphagia needs to be dealt with promptly and almost independently of 
the general condition of the patient. In the rapidly deteriorating patient, oesophageal 
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stenting alone is recommended since it promptly secures a continuity passing the 
obstructing tumour and is usually a single therapy without need for follow-up.114 The 
malnutrition seen in palliative oesophageal cancer patients is typically worse than that of 
most other cancer patients and depending on the clinical scenario enteral support may be 
considered. Deterioration in HRQOL is often rapid, which stresses the urgency in planning for 
the end of life care, and discussing the future with the patient and family members; and 
making early contact with the relevant healthcare facilities, e.g. ambulant palliative care 
unit, hospice or hospitals providing end of life care. Also in the many patients who have 
undergone curatively intended treatment, but develop tumour recurrence, it is 
recommended that palliative and supportive care is planned as soon as recurrent disease is 
discovered. Well-designed clinical trials using standardised measures may help improve the 
best supportive care in oesophageal cancer patients.145, 146  
 
Controversies and uncertainties 
Endoscopic treatment 
Although early tumours (T1) are not often identified, it is important to evaluate when 
endoscopic (organ-sparing) treatment can be recommended above surgical resection. There 
is a need for more large-scale observational research and RCTs to determine the answer to 
this question.  
 
Oncological treatment 
There is a need to clarify the role of neoadjuvant chemotherapy versus chemoradiotherapy. 
Both are associated with tumour down-staging, but rates of complete tumour response are 
higher following chemoradiotherapy, particularly for patients with OSCC.57, 60, 64, 65 However, 
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for patients with OAC, there is concern that the low dose of systemic chemotherapy in 
neoadjuvant chemoradiotherapy regimens may negatively impact on systemic disease 
control. In the long-term follow-up of the CROSS trial, distant metastatic recurrence was 
reduced overall (HR 0.63, 95% CI 0.46-0.87), however this was not significantly not reduced 
after two years compared to the control arm.60 For OAC patients at high risk of metastatic 
recurrence, a systemic approach may be preferred. RCTs are needed to clarify these issues.  
 
Timing of surgery following neoadjuvant therapy 
The tumour stage after neoadjuvant chemoradiotherapy seems to be a better predictor of 
long-term prognosis than clinical tumour stage at presentation.147 Some recent studies 
indicate that an increase in the time latencies between completed neoadjuvant therapy and 
surgery from currently 4-6 weeks to over 12 weeks may improve the tumour response to 
neoadjuvant therapy in OSCC and OAC, which may increase the rate of radical resection.148, 
149 The optimal interval between neoadjuvant therapy and surgery in relation to survival is 
being assessed in an RCT (NCT02415101).  
 
Follow-up 
There is limited evidence on how to optimise the follow-up of patients having undergone 
radical treatment for oesophageal cancer. Some studies indicate that HRQOL measures can 
be used to identify the need for prompt interventions following treatment and also to 
predict survival.35, 150-152 Future research on these topics can provide further evidence that 
might guide future decision-making regarding choice of therapy as well as tailored follow-up. 
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Outstanding research questions 
Detection 
Increased detection of premalignant lesions and early stage tumours would improve 
prognosis. However, general endoscopic screening might not be cost-effective or clinically 
feasible, or well-tolerated by individuals. Future alternatives might be screening of carefully 
selected absolute high-risk individuals (with a combination of risk factors) in combination 
with use of less invasive screening tools, e.g. Cytosponge or breath tests,153, 154 although 
more research is needed before these tools may be introduced in routine clinical practice. 
 
Diagnostics 
Many oesophageal cancer patients undergo extensive therapy despite having tumour 
dissemination that has remained undetected prior to treatment. These patients may never 
recover from surgery before death. Thus, there is a need to develop new diagnostic 
measures with improved specificity and sensitivity for a more accurate assessment of the 
clinical tumour stage, potentially by developing novel radiotracers.  
 
Biomarkers 
New biomarkers that can help predict treatment response and prognosis would be valuable. 
Beyond HER2, there are no biomarkers for treatment selection for patients with operable 
oesophageal cancer. In essence, optimisation and developments in existing therapeutic tools 
can further improve the survival in oesophageal cancer. However, novel strategies for early 
tumour detection and new treatment are required for breakthroughs in the prognosis.  
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Search strategy and selection criteria 
We searched the databases PubMed, Cochrane Library, MEDLINE, and EMBASE. We used the 
search terms “(o)esophageal” or “(o)esophagus” in combination with the terms “cancer” or 
“neoplasm” or “adenocarcinoma” or “squamous cell carcinoma”. We largely selected 
publications from the past 5 years. Review articles and book chapters are cited to provide 
readers with more details and more references than this seminar has room for.  
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Table 1: Frequently dysregulated genes in oesophageal squamous cell carcinoma (OSCC) 
and oesophageal adenocarcinoma (OAC) as per Oesophageal Cancer Genome Atlas.  
 
  
  
 OSCC OAC 
Receptor Tyrosine Kinases 
ERBB2 3% 32% 
EGFR 19% 15% 
VEGFA 3% 28% 
KRAS 7% 14% 
PIK3CA 13% 3% 
FGFR1 12% 4% 
Cell cycle regulators 
CDKN2A 76% 76% 
CCND1 57% 15% 
CDK6 16% 14% 
CCNE1 4% 14% 
RB 9% 0% 
Proliferation and differentiation  
MYC 23% 32% 
SMAD4 8% 24% 
GATA4 1% 19% 
GATA6 3% 21% 
TP63/SOX2 48% 11% 
Chromatin remodelling 
KDM6A 19% 4% 
KMT2D 14% 1% 
Red signifies activation of pathway, blue inactivation.  
Dysregulation may occur via amplification, deletion, 
mutation or epigenetic modulation. 
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Table 2: Selected randomised clinical trials adjunctive therapy for operable oesophageal cancer.  
Trial 
acronyme* 
Tumour histology 
 
Number 
of 
patients  
Treatment 5 year survival in % 
 
Hazard ratio (95% 
confidence interval) 
Median survival in 
months  
Hazard ratio (95% 
confidence interval) 
Neoadjuvant chemotherapy 
 
OEO2 
 
 
Squamous cell carcinoma 33.5% 
Adenocarcinoma 66.5% 
 
802 
 
Surgery (reference) 
Neoadjuvant chemotherapy 
 
17 
23 
 
 
Not reported 
Not reported  
0.83 (0.70-0.98) 
 
Perioperative chemotherapy 
 
MAGIC  
 
 
Adenocarcinoma 100%  
(Lower oesophageal/junctional 26%) 
 
 
503 
 
Surgery (reference) 
Perioperative chemotherapy 
 
23 
36 
 
 
 
Not reported 
Not reported 
0.75 (0.60-0.93) 
 
FNCLCC-
FFCD 
 
 
Adenocarcinoma 100% 
(Lower oesophagus 11%; junctional 64%) 
 
224 
 
Surgery (reference) 
Perioperative chemotherapy 
 
24 
38 
 
 
Not reported  
Not reported 
0.69 (0.50-0.95) 
Pre-operative chemoradiotherapy 
 
CROSS 
 
 
Squamous cell carcinoma 26% 
Adenocarcinoma 74%  
 
 
366 
 
Surgery (reference) 
Neoadjuvant chemoradiotherapy 
 
33 
47 
0.67 (0.51-0.87) 
 
24  
49 
0.68 (0.53-0.88) 
